ライフサイエンスコーパス: peripheral T-cell lymphoma

1 transplant lymphoproliferative disorder, and peripheral T cell lymphoma.

2 f SYK, and it is believed to be the cause of peripheral T cell lymphoma.

3 with large-cell transformation), and two had peripheral T-cell lymphoma.

4 k profile in treating relapsed or refractory peripheral T-cell lymphoma.

5 ge B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma.

6 (ALCL) is the most common type of pediatric peripheral T-cell lymphoma.

7 ted T-cell lymphoma (EATL) is a rare type of peripheral T-cell lymphoma.

8 stigation for the treatment of patients with peripheral T-cell lymphoma.

9 ne (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.

10 e T-cell leukemia (T-ALL) and in a subset of peripheral T-cell lymphomas.

11 a, adult T-cell leukemia/lymphoma, and other peripheral T-cell lymphomas.

12 ed adult T-cell leukaemia-lymphoma and other peripheral T-cell lymphomas.

13 progress in changing the natural history of peripheral T-cell lymphomas.

14 of lymphomas, which included a large set of peripheral T-cell lymphomas.

15 n TEL-FGFR3 associated with t(4;12)(p16;p13) peripheral T-cell lymphomas.

16 anaplastic large-cell lymphomas, 2/12 nodal peripheral T-cell lymphomas, 1/3 CD8+ cutaneous T-cell l

17 ated HD (100%) and EBV+ Malaysian and Danish peripheral T-cell lymphomas (100%, 61% respectively), bu

18 57 (63%) patients had peripheral T-cell lymphoma, 14 (16%) had adult T-cell le

19 as (15.3%), classic Hodgkin lymphomas (13%), peripheral T-cell lymphomas (6.3%) of which angioimmunob

20 ients (aged >=18 years) with newly diagnosed peripheral T-cell lymphoma across 11 countries in Latin

21 nsolidation in patients with CD30-expressing peripheral T-cell lymphomas across five academic centres

22 ;q22) translocation was found in a subset of peripheral T cell lymphomas and was shown to result in a

23 ents were reported in 53 (40%) patients with peripheral T-cell lymphoma and 15 (68%) patients with ad

24 rapy was 2.5 (IQR 1.3-4.0) for patients with peripheral T-cell lymphoma and 5.0 (IQR 5.0-7.0) for pat

25 007 revised criteria for malignant lymphoma (peripheral T-cell lymphoma and B-cell non-Hodgkin lympho

26 re organised in two work packages devoted to peripheral T-cell lymphoma and transplantation.

27 le the diagnosis of unusual entities such as peripheral T-cell lymphomas and Hodgkin disease in patie

28 CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF

29 stat in patients with relapsed or refractory peripheral T-cell lymphoma, and its safety in patients w

30 s that can easily be mistaken for intestinal peripheral T-cell lymphoma, and lead to aggressive thera

31 , follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and non-Hodgkin lymphoma not

32 ved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combinatio

33 Peripheral T cell lymphomas are typically aggressive wit

34 Peripheral T-cell lymphomas are aggressive non-Hodgkin l

35 Peripheral T-cell lymphomas are an uncommon and heteroge

36 The genetics of peripheral T-cell lymphomas are poorly understood.

37 rior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant im

38 is study was to compare in a large series of peripheral T cell lymphoma, as a model of diffuse diseas

39 FGFR3 TDII-induced pre-B cell lymphoma, or a peripheral T-cell lymphoma associated TEL-FGFR3 fusion-i

40 ve been approved for relapsed and refractory peripheral T-cell lymphomas based on their activity, alt

41 se clinical trials on these rare subtypes of peripheral T-cell lymphoma by integrating Latin American

42 1979 patients diagnosed with peripheral T-cell lymphoma by pathology, between 2000 an

43 status (PS) >/= 2; the Prognostic Index for Peripheral T-Cell Lymphoma, comprising: age >/= 60 years

44 e animal model may help our understanding of peripheral T-cell lymphoma development.

45 ith newly diagnosed, untreated CD30-positive peripheral T-cell lymphomas, Eastern Cooperative Oncolog

46 c T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities.

47 In this study, we aimed to describe peripheral T-cell lymphoma epidemiology across Latin Ame

48 Previous studies evaluating peripheral T-cell lymphoma epidemiology across Latin Ame

49 ore aggressive variants of mature B-cell and peripheral T-cell lymphomas exhibit nuclear expression o

50 bocytopenia (31 [23%] of 133 patients in the peripheral T-cell lymphoma group and 11 [50%] of 22 pati

51 aluable patients with relapsed or refractory peripheral T-cell lymphoma had an objective response.

52 one dose and whose pathological diagnosis of peripheral T-cell lymphoma had been retrospectively conf

53 a number of T-cell diseases, including some peripheral T-cell lymphomas, hemophagocytic lymphohistio

54 (HCT) is a potentially curative therapy for peripheral T-cell lymphoma; however, to date, there are

55 treated patients with relapsed or refractory peripheral T-cell lymphoma in a phase 1 study (JACKPOT8

56 scores the unique epidemiological profile of peripheral T-cell lymphoma in Latin America, with a high

57 Two of three peripheral T-cell lymphomas--including one anaplastic la

58 th fulminant hepatic failure from an unusual peripheral T cell lymphoma involving the liver and splee

59 eatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma is potential cure, during whi

60 antigen expression in the classification of peripheral T-cell lymphomas is still unclear.

61 xate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) is the largest prospective s

62 astic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence.

63 ally for the broader category of the disease-peripheral T-cell lymphoma-let alone any of the specific

64 ligible patients with refractory or relapsed peripheral T-cell lymphoma, leveraging its curative pote

65 ults in the induction of an acute and lethal peripheral T cell lymphoma-like disease (PTCL), named ma

66 22, 133 patients with relapsed or refractory peripheral T-cell lymphoma (median age 69.0 years [IQR 5

67 ogies included DLBCL (n = 21), MCL (n = 13), peripheral T-cell lymphoma (n = 8), transformed follicul

68 ymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphoma

69 e observed between Hodgkin lymphoma (HL) and peripheral T-cell lymphoma not otherwise specified (PTCL

70 nts (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 a

71 le to successfully separate ALK(-) ALCL from peripheral T-cell lymphoma not otherwise specified, with

72 s, 9 angioimmunoblastic T-cell lymphomas, 11 peripheral T-cell lymphomas not otherwise specified (PTC

73 ngioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, not otherwise specified (PTC

74 Peripheral T-cell lymphoma, not otherwise specified (PTC

75 mphoma (AITL) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTC

76 Compared with peripheral T-cell lymphoma, not otherwise specified and

77 The most common PTCLs, peripheral T-cell lymphoma, not otherwise specified, ang

78 Peripheral T-cell lymphoma, not otherwise specified, is

79 The most common subtype was peripheral T-cell lymphoma, not otherwise specified; the

80 phoma, including eight children with typical peripheral T-cell lymphomas of various types.

81 Patients with either peripheral T-cell lymphoma or adult T-cell leukaemia/lym

82 aged >=18 years) with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma,

83 ted by T-cell responses were associated with peripheral T-cell lymphoma (OR = 2.14, 95% CI: 1.35, 3.3

84 There was an increased OR for peripheral T-cell lymphoma (OR = 2.42, 95% CI, 1.24-4.72

85 In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic la

86 A frame-shift ATM mutation was found in one peripheral T cell lymphoma patient.

87 Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma presenting mostly in children

88 The International Peripheral T-cell Lymphoma Project is a collaborative ef

89 The International Peripheral T-Cell Lymphoma Project was undertaken to bet

90 nitial therapy for people with CD30-positive peripheral T-cell lymphomas prolonged progression-free s

91 Peripheral T cell lymphoma (PTCL) is a heterogeneous gro

92 A newly developed model of peripheral T cell lymphoma (PTCL) using the ITK-SYK fusi

93 n addition, a significant subset of cases of peripheral T cell lymphoma (PTCL), 39 of 81 cases (48%),

94 lymphocytic leukemia (CLL) and CD8-positive peripheral T cell lymphomas (PTCL) in EmuSRalpha-tTA;Tet

95 Peripheral T-cell lymphoma (PTCL) and natural killer/T-c

96 Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclo

97 ion of Lin28b in vivo leads to an aggressive peripheral T-cell lymphoma (PTCL) characterized by wides

98 AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with auto

99 Peripheral T-cell lymphoma (PTCL) encompasses a heteroge

100 sed as consolidation for several subtypes of peripheral T-cell lymphoma (PTCL) in first remission.

101 Rare subtypes of peripheral T-cell lymphoma (PTCL) including enteropathy-

102 Peripheral T-cell lymphoma (PTCL) is a heterogeneous gro

103 Peripheral T-cell lymphoma (PTCL) is a heterogeneous gro

104 Peripheral T-cell lymphoma (PTCL) is a poor prognosis su

105 Peripheral T-cell lymphoma (PTCL) is a rare and heteroge

106 Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneo

107 Peripheral T-cell lymphoma (PTCL) is often challenging t

108 T-cell clonality of peripheral T-cell lymphoma (PTCL) is routinely evaluated

109 ng CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after

110 For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontl

111 nal Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL).

112 common among tumor and nontumor cells within peripheral T-cell lymphoma (PTCL).

113 homa (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL).

114 , but very little is known about the risk in peripheral T-cell lymphoma (PTCL).

115 ntuximab vedotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).

116 T) that mimics inflammatory bowel disease or peripheral T-cell lymphoma (PTCL).

117 psin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

118 a collaborative effort to better understand peripheral T-cell lymphoma (PTCL).

119 12), mantle cell lymphoma (MCL; n = 7), and peripheral T-cell lymphoma (PTCL; n = 5).

120 Peripheral T-cell lymphomas (PTCL) are a group of rare m

121 The peripheral T-cell lymphomas (PTCL) are a heterogeneous g

122 Peripheral T-cell lymphomas (PTCL) are aggressive diseas

123 Peripheral T-cell lymphomas (PTCL) are agressive lymphom

124 Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens suc

125 Peripheral T-cell lymphomas (PTCL) with T-follicular hel

126 Peripheral T cell lymphomas (PTCLs) are a heterogeneous

127 Peripheral T cell lymphomas (PTCLs) are a heterogeneous

128 Peripheral T cell lymphomas (PTCLs) are a heterogeneous

129 Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumor

130 Peripheral T cell lymphomas (PTCLs) are heterogeneous ne

131 Peripheral T cell lymphomas (PTCLs) represent a signific

132 Among patients with peripheral T cell lymphomas (PTCLs), overall and complet

133 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous

134 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous

135 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous

136 Peripheral T-cell lymphomas (PTCLs) are aggressive malig

137 Peripheral T-cell lymphomas (PTCLs) are heterogenous T-c

138 Peripheral T-cell lymphomas (PTCLs) are rare lymphomas w

139 The peripheral T-cell lymphomas (PTCLs) are uniquely sensiti

140 Peripheral T-cell lymphomas (PTCLs) are uniquely vulnera

141 Peripheral T-cell lymphomas (PTCLs) encompass a heteroge

142 The peripheral T-cell lymphomas (PTCLs) encompass a heteroge

143 Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clin

144 Peripheral T-cell lymphomas (PTCLs) represent a diverse

145 Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to co

146 cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understo

147 dotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising effic

148 Peripheral T-cell lymphomas (PTCLs), especially angioimm

149 The treatment of common nodal peripheral T-cell lymphomas (PTCLs), including PTCL, not

150 ts with relapsed or refractory cutaneous and peripheral T-cell lymphomas (PTCLs).

151 nt's role remain elusive for the most common peripheral T-cell lymphomas (PTCLs).

152 in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs).

153 in has opened a new era in the management of peripheral T-cell lymphomas (PTCLs).

154 e differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwi

155 anned subset analysis included patients with peripheral T-cell lymphomas (PTCLs; n = 35), specificall

156 r more commonly, from mature T and NK cells (peripheral T-cell lymphomas, PTCLs).

157 ce in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r/r PTCL), resulting in hig

158 t T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dos

159 Peripheral T-cell lymphomas represent a rare and heterog

160 arge B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively.

161 absence of a mass lesion or lymphadenopathy, peripheral T cell lymphoma should be included in the dif

162 eity, a paucity of cases, and the absence of peripheral T-cell lymphoma-specific drugs, until recentl

163 One hundred six patients with peripheral T cell lymphoma, staged with PET/CT, were enr

164 ed valemetostat and had a confirmed eligible peripheral T-cell lymphoma subtype on central review wer

165 ive adult T-cell leukaemia-lymphoma or other peripheral T-cell lymphoma subtypes, and at least one pr

166 The main outcomes were prevalence of peripheral T-cell lymphoma subtypes, overall survival, e

167 cell lymphoma and is expressed in some other peripheral T-cell lymphoma subtypes.

168 ries with previously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic

169 gioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell lymphoma that originates from T follic

170 In this model of mature peripheral T cell lymphomas, the cell of origin was a ma

171 In patients with Hodgkin's lymphoma and peripheral T-cell lymphoma, treatment with bendamustine

172 a had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete

173 Here, we investigate the origin of peripheral T cell lymphomas using mice in which Snf5, a

174 The primary endpoint for patients with peripheral T-cell lymphoma was the CT-based objective re

175 Historically, peripheral T-cell lymphomas were treated with strategies

176 aged >=18 years) with relapsed or refractory peripheral T-cell lymphoma who had received at least one

177 ho had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma with prominent cutaneous dise

178 ll lymphoma (AITL) is the second most common peripheral T-cell lymphoma with unusual clinical and pat

179 T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis.

180 nses in patients with relapsed or refractory peripheral T-cell lymphoma, with a manageable safety pro

181 motherapy because of an initial diagnosis of peripheral T-cell lymphoma, with little or no response,